This page shows the latest Merck and Co. news and features for those working in and with pharma, biotech and healthcare.
In December 2022, a personalised mRNA cancer vaccine from Moderna and Merck &Co – known as MSD outside the US and Canada – was shown to benefit patients with high-risk melanoma. ... In October 2022, the companies announced that Merck had exercised
A new prostate cancer awareness campaign titled‘Never Miss’ has been launched by AstraZeneca (AZ) in partnership with MSD – known as Merck &Co in the US and Canada. ... also supporting them in feeling able to speak openly with family and friends.
The treatments are for use in prostate, biliary tract and advanced gastric cancer. ... The final recommendation was for AZ and MSD’s – known as Merck &Co in the US and Canada – Lynparza (olaparib) in combination with abiraterone and prednisone or
MSD's – known as Merck &Co in the US and Canada – Vaxneuvance (PCV15) has been approved in the UK for the prevention of invasive disease, pneumonia and acute otitis media caused ... pre-term infants and children living with HIV infection or sickle
The National Institute for Health and Care Excellence (NICE) has rejected AstraZeneca (AZ) and MSD’s – known as Merck &Co in the US and Canada – Lynparza (olaparib), following an unsuccessful discussion ... has spread to other parts of the body and
AstraZeneca (AZ) and MSD’s – known as Merck &Co in the US and Canada – Lynparza (olaparib) has been approved by the European Commission (EC) for the treatment of patients with germline ... The phase 3 trial is a double-blind, multicentre study
More from news
Approximately 44 fully matching, plus 523 partially matching documents found.
By Sandy Lindsey. It’s little over a year since the bell first rang on the New York Stock Exchange announcing the arrival of Organon &Co, a spin-off from MSD ... known as Merck &Co in the US and Canada) with a mission to create improved health outcomes
Similarly, Novartis formed the investment firm Novartis Venture Funds and Merck &Co. ... created the Merck Research Venture Fund. Nowadays, having a venture arm to proactively research for outside R&D sourcing is common for most mid- to large- sized
Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... Bayer and Merck &Co hope that radiologists
like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.
Ex-Merck &Co. scientist Joshua Boger did want the company to pioneer rationale drug discovery and development, however, and after. ... a loss in almost all of its 20+ years, and has cumulative net losses of around $3bn.
More from intelligence
Approximately 0 fully matching, plus 45 partially matching documents found.
Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health. ... Clyburn joined Merck &Co in 2008 and during his time with the company, he has had responsibility for various global
Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.
Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.
Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in
He has been with the pharma company since 2010, when he joined from Schering-Plough (now part of Merck &Co) and subsequently held positions of increasing responsibility. ... In his new role Fiordaliso will report to Stephen Knowles, senior vice president
More from appointments
Approximately 4 fully matching, plus 34 partially matching documents found.
Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.
With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...